Boston Scientific shares climbed 7.1% after the company reported second-quarter 2026 sales of US$5,442 million and net income of US$907 million, while also issuing a recall of its Rapid Refill Continuous Injection System and launching a multi-year global restructuring plan. The restructuring program is expected to cost up to US$800 million and aims to deliver approximately US$500 million in annual pre-tax expense reductions by 2029. The company raised its full-year 2026 net sales growth outlook to roughly 5.5% to 6.5%. The restructuring is designed to protect profitability amid pressures in electrophysiology and left atrial appendage closure, potentially freeing resources for reinvestment in higher-growth areas like FARAPULSE and WATCHMAN.
Boston Scientific CorpQ2 earnings beat and raised full-year sales outlook